Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.59 |
| ▸ | RARB | P10826 | 1/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.57 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.57 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8947144 | 0.94 | RARB (0.69) | ALDH1A1HSD17B10HPGDFFAR1L3MBTL1 | |
| SCHEMBL6285855 | 0.94 | ALDH1A1 (0.72) | ALDH1A1HSD17B10HPGDFFAR1L3MBTL1 | |
| SCHEMBL6286434 | 0.92 | ALDH1A1 (0.70) | ALDH1A1HSD17B10HPGDFFAR1LMNA | |
| SCHEMBL2185948 | 0.92 | ALDH1A1 (0.70) | ALDH1A1HSD17B10HPGDFFAR1LMNA | |
| SCHEMBL20854085 | 0.92 | ALDH1A1 (0.70) | ALDH1A1HSD17B10HPGDFFAR1LMNA | |
| SCHEMBL10435207 | 0.92 | ALDH1A1 (0.70) | ALDH1A1HSD17B10HPGDFFAR1LMNA | |
| SCHEMBL6288014 | 0.92 | ALDH1A1 (0.70) | ALDH1A1HSD17B10HPGDFFAR1LMNA | |
| SCHEMBL10482320 | 0.92 | HSD17B10 (0.71) | ALDH1A1HSD17B10HPGDFFAR1L3MBTL1 | |
| SCHEMBL20853926 | 0.90 | ALDH1A1 (0.69) | ALDH1A1HSD17B10HPGDRARBS1PR1 | |
| SCHEMBL7338308 | 0.89 | RARB (0.70) | ALDH1A1HSD17B10HPGDFFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2022-02-22 | — | — | US | claimed |
| US-20200405863-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | NOVO NORDISK A/S (DK) | 2020-12-31 | — | — | US | claimed |
| EP-2114145-B1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECH INC (US) | 2017-11-01 | — | — | EP | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| CN-106456662-A | Compositions of pentosan polysulfate for oral administration and methods of use thereof | 奥利金制药公司 | 2017-02-22 | — | — | CN | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| CN-105233294-A | Phenylalkylcarboxylic acid delivery agent | EMISPHERE TECH INC | 2016-01-13 | — | — | CN | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-20120258911-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2012-10-11 | — | — | US | claimed |
| US-20110046050-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-02-24 | — | — | US | claimed |
| CN-101616583-A | Phenylalkylcarboxylic acid delivery agents | EMISPHERE TECH INC | 2009-12-30 | — | — | CN | claimed |
| EP-2114145-A2 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | Emisphere Technologies, Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008112368-A2 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-09-18 | — | — | WO | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2024098361-A1 | ARTIFICIAL NUCLEIC ACID MOLECULE | 斯微(上海)生物科技股份有限公司 | 2024-05-16 | — | — | WO | disclosed |
| CN-117396590-A | Perfume for improving relaxation state and evaluation method | 奇华顿股份有限公司 | 2024-01-12 | — | — | CN | disclosed |
| EP-2114145-A2 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | Emisphere Technologies, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008112368-A2 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112368-A2 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405863-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | PGF, LIPA, PDGFA | ALDH1A1 599/4885HSD17B10 1647/4885HPGD 1242/4885 |
| US-20110046050-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | PGF, LIPA, PDGFA | ALDH1A1 599/4885HSD17B10 1647/4885HPGD 1242/4885 |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | PGF, LIPA, PDGFA | ALDH1A1 599/4885HSD17B10 1647/4885HPGD 1242/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | ALDH1A1 3725/4885HSD17B10 1827/4885HPGD 1489/4885 |
| US-20120258911-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | PGF, LIPA, PDGFA | ALDH1A1 599/4885HSD17B10 1647/4885HPGD 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.